ChemoMetec Boosts Financial Outlook Amid Growing Interest
ChemoMetec is excited to announce an upgrade in its financial guidance as the company sees a growing demand for its pioneering technologies, particularly the highly regarded XcytoMatic platform. This surge in interest bodes well for the company's revenue and profit, reflecting a positive trajectory as it approaches the latter half of the fiscal year.
Increased Revenue Expectations
The financial projections for the fiscal year 2025/26 have seen a promising shift, with revenue expectations revised to a range of DKK 565-580 million. This is a noticeable increase from the previously announced forecast of DKK 545-565 million. Such optimism is grounded in the trends observed and the expanding market for ChemoMetec's innovative technologies.
EBITDA Forecast Adjustment
Alongside revenue growth, ChemoMetec is also updating its EBITDA expectations. The anticipated range is now set between DKK 320-335 million, improving upon the earlier forecast of DKK 295-315 million. This upward revision indicates the firm’s solid financial health and operational efficiency in managing costs and maximizing profit potential.
Upcoming Trading Statement
The company is scheduled to release its Q1 trading statement for the fiscal year 2025/26. Investors and stakeholders can look forward to this announcement on 6 November 2025. This statement will provide further insights into the company’s performance and outlook.
Leadership Commitment
Martin Helbo Behrens, the CEO of ChemoMetec, emphasizes their commitment to delivering exceptional technology and value to their customers across various sectors including pharmaceuticals, biotechnology, and agriculture. The leadership team, which includes CFO Kim Nicolajsen, is dedicated to steering the company towards sustainable growth and innovation.
About ChemoMetec A/S
ChemoMetec has carved a niche in the development, manufacturing, and marketing of sophisticated instruments for cell counting and various measurement applications. Their products cater to a diverse array of markets, particularly focusing on pharmaceutical, biotech, and agricultural industries worldwide. Some of the leading global pharmaceutical companies rely on ChemoMetec's state-of-the-art instruments, underscoring the company's significant role in healthcare technology.
Established in 1997, ChemoMetec is publicly traded on Nasdaq OMX Copenhagen, showcasing its long-standing presence and credibility in the market. For further information about the company and its groundbreaking technologies, you can visit their official site www.chemometec.com.
Frequently Asked Questions
What recent changes have been made to ChemoMetec's financial guidance?
ChemoMetec has updated its revenue expectations for the fiscal year 2025/26, increasing the forecast to a range of DKK 565-580 million.
How does the upgraded EBITDA forecast impact ChemoMetec?
The EBITDA expectations have also been raised to DKK 320-335 million, reflecting the company's operational efficiency and positive market trends.
What technology is driving growth for ChemoMetec?
The XcytoMatic platform is currently driving significant interest and expected revenue growth for ChemoMetec.
When will ChemoMetec release its quarterly trading statement?
The trading statement for Q1 2025/26 is scheduled to be released on 6 November 2025.
What industries benefit from ChemoMetec's instruments?
ChemoMetec’s instruments are primarily utilized in the pharmaceutical, biotech, and agricultural industries.
